|
a. Postoperative radiotherapy of the chest wall after
mastectomy reduces the risk of locoregional
recurrence. |
Level of evidence
1a
|
(Clarke M et al. 2005; EBMG 2006; NCCN 2011; NHMRC2001;
NICE 2009; NZGG 2009; Peto R 2006; Shafiq J et al. 2007;
SIGN 2005; Whelan T et al. 2007) |
|
b. In patients with a high risk of a local recurrence,
overall survival is also improved. |
Level of evidence
1a
|
(Clarke M et al. 2005; Darby S et al. 2009; Fernando SA
et al. 2007; Gebski V et al. 2006; Harris EE 2008; Jagsi
R et al. 2009; Kyndi M et al. 2008b; Kyndi M et al.
2008a; NCCN 2011; NICE 2009; Nielsen HM et al. 2006a;
Nielsen HM et al. 2006b; NZGG 2009; Overgaard M et al.
2007; Peto R 2006; Poortmans P 2007; Rowell NP 2009;
Rowell NP 2010; Voordeckers M et al. 2009; Whelan T et
al. 2007) |
|
c. Postoperative radiotherapy of the chest wall after
mastectomy is therefore indicated in the following
situations: |
Grade of recommendation
A
|
|
Level of evidence
1a
|
(NCCN 2011; NICE 2009; NZGG 2009) |
Grade of recommendation
B
|
pT3 pN0 R0 only in the presence of other risk
factors (lymphatic vessel invasion, G3 grade,
close resection margin, premenopausal status, age
< 50 years)
|
Level of evidence
2b
|
(Floyd SR et al. 2009; Kunkler I 2010; McCammon R et al.
2008; Rowell NP 2009; Russell NS et al. 2009) |
Grade of recommendation
A
|
|
Level of evidence
1a
|
(NCCN 2011; NICE 2009; NZGG 2009) |
Grade of recommendation
A
|
|
Level of evidence
1a
|
(NCCN 2011; NICE 2009; NZGG 2009) |
Grade of recommendation
A
|
d. After primary (neoadjuvant) systemic therapy, the
indication for radiotherapy should be based on the
pretherapeutic T and N category, regardless of the
degree of response to the primary systemic therapy. |
Level of evidence
2a
|
(Buchholz TA et al. 2002; Buchholz TA et al. 2008;
Buchholz TA 2009; Garg AK et al. 2007; Goldhirsch A et
al. 2009; Huang EH et al. 2006; Kaufmann M et al. 2003;
Kaufmann M et al. 2010; NCCN 2007; NCCN 2011) |